Safety trial using the Leishmune® vaccine against canine visceral leishmaniasis in Brazil

Parra, L.E.; Borja-Cabrera, G.P.; Santos, F.N.; Souza, Lucieri O.P.; Palatnik-de-Sousa, Clarisa B.; Menz, Ingrid

doi:10.1016/j.vaccine.2006.11.057

Cited by 61 publications

(58 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most studied second-generation vaccine candidate is fucosemannose ligand (FML), isolated first from L. donovani and chemically characterized by Palatnik de Sousa et al [96] and now commercially available under the name of Leishmune® (patent INPI number: PI1100173-9, Federal University of Rio de Janeiro, Brazil) for the treatment of dogs in Brazil [151]. The antigen was found to be present on the surface of the parasite throughout the life cycle and strongly inhibited the in vitro internalization of macrophages by both promastigotes and amastigotes of various species of Leishmania [96,152].…”

Section: Fmlmentioning

confidence: 99%

Vaccine candidates for leishmaniasis: A review

Nagill

Kaur

2011

International Immunopharmacology

111

View full text Add to dashboard Cite

Section: Fmlmentioning

confidence: 99%

Vaccine candidates for leishmaniasis: A review

Nagill

Kaur

2011

International Immunopharmacology

111

View full text Add to dashboard Cite

“…Two vaccines, Leishmune ® (Parra et al, 2007) and Leish-Tec ® (Fernandes et al, 2014), use saponin as an adjuvant in their compositions. Saponins, natural glycosides derived from steroid or triterpene, exhibited different biological and pharmacological activities.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis

Pereira

Régis

Costa

et al. 2015

Experimental Parasitology

View full text Add to dashboard Cite

“…C) DNA, recombinant proteins vaccines and combinations: To stimulate lifelong protection, genetically altered Leishmania parasites are used because they lack cystein proteases or dyhydrofolate reductase enzyme [56]. In case of canine VL saponin formulation of fucose mannose ligand was found to be safe and is licensed as Leishmune (76-80% protection) veterinary vaccine [57]. The antibodies (Abs) produce by this vaccine do not allow the development of promastigote in fly.…”

Section: Vaccination Agent Referencementioning

confidence: 99%

Mammalian Parasitic Vaccine: A Consolidated Exposition

Sumbria¹,

Singla²

2015

J Vaccines Immun

View full text Add to dashboard Cite

Parasites are highly prevalent in livestock worldwide and infect over one fourth of the human population also. Parasites are successful in evading host immune responses, and vaccination can prove to be an effective way to control them. However, currently very few vaccines are available against parasitic infection. Two important limitations in the emergence of effective parasitic vaccines are incomplete understanding of the immunoregulatory pathways involved in immunity, and the lack of precise information regarding host-pathogen interactions. Precise identification of parasite genes and the role of their products in parasite biology may assist in the identification of useful antigens, which could then be produced in recombinant systems. Many recombinant parasitic antigens have been successfully used in livestock and new vaccines are under trail. Numerous vaccine antigens are defined to target a wide range of parasite species. Thus vaccines offer a green solution to control disease. Vaccines have multiple beneficial effects such as improvement of animal health and welfare by controlling animal infestations and infections; diminishing resistance to anthelmintics, acaricides and antibiotics; improving public health status by controlling food borne pathogens and zoonoses aspect related to animals; keeping animals and the environment free of chemical residues and maintaining biodiversity. This current review is an attempt to consolidate all commercial or under-trail vaccine for mammalian parasites.$ 64.6 million are lost in productivity losses. The average total costs for persons with mild, moderate, and severe illness were $116, $475, and $7,808, respectively [7,8]. In order to come out from adverse effect of these parasites an urge of effective control is needed. Up till now the control strategy of parasites relies mainly on the use of chemotherapy like anthelminthes, antiprotozoal drugs and insecticides etc, as they are safe, cheap and effective against a broad spectrum of parasites [9,10]. But indiscriminate use of these drugs led to the emergence of drug resistance in many targeted parasites [11]. On the same time, issues of residues in the food chain and environment have arisen, which threaten their sustained use [12]. So scientist and researcher are now a days concentrating on development of alternate sustainable methods like vaccinations, novel therapeutic regimens and immnuomodulations against these parasite [2]. The term "vaccine" was first coined by Edward Jenner in 1881; it was derived from Variolae vaccinae (smallpox of the cow). Vaccines are used to generate antibodies and boost immunity against a disease, and usually contain an agent which may be the microorganism, its product, toxins or one of its surface proteins, treated/modified to be used as an antigen without causing disease [13]. It can be prophylactic or therapeutic. Vaccination helps in the development of acquired immunity by inoculating non-pathogenic but immunogenic components of the pathogen, or closely related organisms. In animal ...

show abstract

Safety trial using the Leishmune® vaccine against canine visceral leishmaniasis in Brazil

Cited by 61 publications

References 38 publications

Vaccine candidates for leishmaniasis: A review

Vaccine candidates for leishmaniasis: A review

Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis

Mammalian Parasitic Vaccine: A Consolidated Exposition

Contact Info

Product

Resources

About